Diaceutics (GB:DXRX) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Diaceutics PLC is expanding its US commercial activities by executing multiple data partnership agreements, contributing to a first-year contract value of £1.13 million. These partnerships are expected to increase revenue and Annual Recurring Revenue by leveraging partner sales teams to sell high-margin data products like DXRX Signal. The company aims to broaden its customer base, tapping into new segments and pharmaceutical brands.
For further insights into GB:DXRX stock, check out TipRanks’ Stock Analysis page.